Alkermes applies its scientific expertise and technological know-how to develop innovative medicines designed to help patients with serious, chronic conditions better manage their disease.
Alkermes to Take Part in SVB Leerink 10th Annual Global Healthcare Conference Read More
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021 Read More
Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results Read More
NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine Read More